How to buy HUTCHMED DRC stock (HCM)

HUTCHMED DRC is a drug manufacturers - specialty & generic business based in the US. HUTCHMED DRC shares (HCM) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $14.61 – a decrease of 6.23% over the previous week. HUTCHMED DRC employs 1,970 staff and has a trailing 12-month revenue of around $610.8 million.

Our top picks for where to buy HUTCHMED DRC stock

Buy HUTCHMED DRC stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

HUTCHMED DRC stock price (NASDAQ: HCM)

Use our graph to track the performance of HCM stocks over time.

HUTCHMED DRC shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$14.61
52-week range	$11.93 - $21.92
50-day moving average more info button	$18.22
200-day moving average more info button	$18.14
Wall St. target price	$28.11
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.25

Is it a good time to buy HUTCHMED DRC stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

HUTCHMED DRC price performance over time

Historical closes compared with the close of $14.48 from 2024-12-18

1 week (2024-12-13)	-7.06%
1 month (2024-11-21)	-18.10%
3 months (2024-09-20)	-16.69%
6 months (2024-06-21)	-19.24%

1 year (2023-12-21)	-14.72%
2 years (2022-12-21)	-1.50%
3 years (2021-12-21)	35.33
5 years (2019-12-20)	25.58

HUTCHMED DRC financials

Revenue TTM	$610.8 million
Gross profit TTM	$-271,587,000
Return on assets TTM	-5.9%
Return on equity TTM	-5.44%
Profit margin	-6.87%
Book value	$0.87
Market Capitalization more info button	$2.6 billion

TTM: trailing 12 months

HUTCHMED DRC share dividends

We're not expecting HUTCHMED DRC to pay a dividend over the next 12 months.

Have HUTCHMED DRC's shares ever split?

HUTCHMED DRC's shares were split on 29 May 2019 .

HUTCHMED DRC share price volatility

Over the last 12 months, HUTCHMED DRC's shares have ranged in value from as little as $11.9343 up to $21.92. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while HUTCHMED DRC's is 0.746. This would suggest that HUTCHMED DRC's shares are less volatile than average (for this exchange).

HUTCHMED DRC overview

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd. , Inmagene Biopharmaceuticals Co. Ltd.

Frequently asked questions

null
What percentage of HUTCHMED DRC is owned by insiders or institutions?
Currently 0.125% of HUTCHMED DRC shares are held by insiders and 4.282% by institutions. How many people work for HUTCHMED DRC?
Latest data suggests 1,970 work at HUTCHMED DRC. When does the fiscal year end for HUTCHMED DRC?
HUTCHMED DRC's fiscal year ends in December. Where is HUTCHMED DRC based?
HUTCHMED DRC's address is: Cheung Kong Center, Hong Kong, Hong Kong What is HUTCHMED DRC's ISIN number?
HUTCHMED DRC's international securities identification number is: US44842L1035 What is HUTCHMED DRC's CUSIP number?
HUTCHMED DRC's Committee on Uniform Securities Identification Procedures number is: 44842L103